← All trials
NCT05430386
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 5, 2022
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Jun 24, 2022
- Last posted
- Jun 24, 2022
- Enrollment
- 174
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Lead sponsor
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Central South UniversityOverall official - principal investigator
- Jilin Provincial Tumor HospitalOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.